• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024

    10/15/24 4:05:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRVI alert in real time by email

    SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

    To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 9502421. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.

    About Maravai

    Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.



    Contact Information:
    Deb Hart
    Maravai LifeSciences
    + 1 858-988-5917
    [email protected]

    Primary Logo

    Get the next $MRVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRVI

    DatePrice TargetRatingAnalyst
    2/26/2025$9.00 → $3.00Outperform → Neutral
    Robert W. Baird
    12/19/2024Neutral
    Guggenheim
    12/5/2024$4.25Neutral → Sell
    Goldman
    11/14/2024Peer Perform
    Wolfe Research
    11/8/2024Outperform → Mkt Perform
    William Blair
    8/28/2024$10.00Overweight
    Wells Fargo
    8/13/2024$11.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    4/10/2024$15.00Buy
    Craig Hallum
    More analyst ratings

    $MRVI
    SEC Filings

    See more
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      6/9/25 8:40:50 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Maravai LifeSciences Holdings Inc.

      SCHEDULE 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      5/29/25 5:24:04 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

      5/28/25 5:26:08 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marker Luke Joseph was granted 89,139 shares, increasing direct ownership by 182% to 138,055 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:09 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gray Susannah was granted 89,139 shares, increasing direct ownership by 110% to 169,907 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:19 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Daverman Benjamin James was granted 89,139 shares, increasing direct ownership by 182% to 138,055 units (SEC Form 4)

      4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

      6/18/25 6:25:28 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maravai Life Sciences downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $3.00 from $9.00 previously

      2/26/25 7:15:06 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Maravai Life Sciences

      Guggenheim initiated coverage of Maravai Life Sciences with a rating of Neutral

      12/19/24 8:13:54 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai Life Sciences downgraded by Goldman with a new price target

      Goldman downgraded Maravai Life Sciences from Neutral to Sell and set a new price target of $4.25

      12/5/24 7:46:04 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/14/24 7:49:19 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 4:48:49 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

      SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

      11/13/24 9:30:19 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

      SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

      6/9/25 8:30:00 AM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

      5/21/25 4:22:17 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maravai LifeSciencesReleases 2024 Sustainability Report

      Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2

      5/21/25 4:05:00 PM ET
      $MRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care